Aprea Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Filed March 1, 2023, under Item 8.01 (Other Events). The filing reports the company’s remediation of a Nasdaq minimum bid-price deficiency.
Material Event
Nasdaq notified Aprea on September 12, 2022 that its common stock had traded below the $1.00 minimum closing bid-price requirement for 30 consecutive business days under Nasdaq Listing Rule 5450(a)(1).
On March 1, 2023, Nasdaq confirmed that Aprea’s common stock closed at or above $1.00 per share for ten consecutive trading days from February 14 through February 28, 2023. Aprea therefore regained compliance, and the matter was closed.
Financial Metrics and Liquidity
This Form 8-K does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
Guidance, Outlook, Risks, and Unusual Items
The filing contains no financial guidance or updated operating outlook. Regaining compliance removes the identified Nasdaq bid-price deficiency; however, continued listing remains subject to applicable Nasdaq requirements.
The company issued a March 1, 2023 press release, filed as Exhibit 99.1. Aprea’s common stock trades under the symbol APRE on the Nasdaq Global Select Market.
Key Facts to Verify
- Verify that Nasdaq’s compliance determination was based on closing prices of at least $1.00 for the ten consecutive trading days specified in the filing.
- Review subsequent filings for any additional Nasdaq listing deficiencies or changes in listing status.
- Review the company’s periodic reports for current financial condition, cash runway, debt, operating results, and development-program risks, none of which are provided in this filing.